ClinicalTrials.gg
CompletedNCT01685801Updated May 19, 2015Results posted

Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With Cystic Fibrosis and Residual CFTR Function

A Phase 2 interventional study of Ivacaftor and Placebo-matched-to-ivacaftor tablet in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 1 site in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2015-05-19.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 84 studies testing ivacaftor in Cystic Fibrosis — 4 open to participants now, 7 under way, 2 of them phase 3. ivacaftor · Cystic Fibrosis.

Enrollment
65th of 84
24 · median 70
Started
2012
with 3 others
Phase 2
17 of 84
none open now
Registered
18th of 84
by date
Lead sponsor
74 of 84
Vertex Pharmaceuticals Incorporated

Among the 84 studies testing ivacaftor in Cystic Fibrosis, this one is the 65th largest by enrollment, is one of 4 that started in 2012, is one of 17 in phase 2, and was the 18th registered.

Cystic Fibrosis

1,622 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

4 of the 84 studies testing ivacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About ivacaftor

ivacaftor: first FDA approval 2012 (KALYDECO), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 87 take children under 18; 42 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies testing ivacaftor in Cystic Fibrosis, or all of them as a file.
02

Study summary

This study is a multiple within participant crossover study to evaluate the effect of ivacaftor on lung function in participants aged 12 years and older with cystic fibrosis (CF) who have phenotypic or molecular evidence of residual CF transmembrane conductance regulator (CFTR) function.

Read the detailed description

CFTR Mutations associated with residual function or defective messenger ribonucleic acid (mRNA) splicing include the following:

R117H, E56K, P67L, D110E, D110H, R117C, R347H, R352Q, A455E, D579G, S945L, L206W, R1070W, F1074L, D1152H, S1235R, D1270N, 2789+5G->A, 3849+10kbC->T, 3272-26A->G, 711+5G->A, 3120G->A, 1811+1.6kbA->G, 711+3A->G, 1898+3A->G, 1898+1G->A, 1717-1G->A, 1717-8G->A, 1342-2A->C, 405+3A->C, 1716G/A 1811+1G->C, 1898+5G->T, 3850-3T->G, IVS14b+5G->A, 1898+1G->T, 4005+2T->C, 621+3A->G, 621+1G->T.

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants with confirmed diagnosis of CF
  • Clinical evidence of residual CFTR function based on any 1 of the following: 1) Clinically documented residual exocrine pancreatic function, 2) Sweat chloride value less than equal to (\<=) 80 millimole per liter (mmol/L) at screening, or 3) Age of diagnosis greater than equal to (>=) 12 years and at least 1 copy of a CFTR mutation associated with residual CFTR function or defective mRNA splicing
  • >= 40 percent (%)
  • 12 years of age or older
  • Willing to agree to meet the requirements
  • Able to swallow tablets

Exclusion criteria

Exclusion Criteria:

  • A copy of any of the following CFTR mutations: G551D, G178R, S549N, S549R, G551S, G970R, G1244E, S1251N, S1255P, or G1349D
  • Unable to perform spirometry
  • An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy (including antibiotics) for pulmonary disease within 4 weeks before Day 1
  • Ongoing participation in another therapeutic clinical study or prior participation in an drug study within the 30 days prior to screening
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Care provider)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Ivacaftor, Placebo, Ivacaftor, Placebo (IPIP)

    During the Crossover Period, study drug was administered in 2-week alternating cycles with a minimum of 4-week washout period between Cycle 1 \[(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)\] and Cycle 2 \[(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)\] and between Cycle 2 and the Open-label Period (Day 1 to 57). During the Open-label Period, all participants received ivacaftor.

    Drug: Ivacaftor · Drug: Placebo-matched-to-ivacaftor tablet

  • Experimental
    Ivacaftor, Placebo, Placebo, Ivacaftor (IPPI)

    During the Crossover Period, study drug was administered in 2-week alternating cycles with a minimum of 4-week washout period between Cycle 1 \[(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)\] and Cycle 2 \[(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)\] and between Cycle 2 and the Open-label Period (Day 1 to 57). During the Open-label Period, all participants received ivacaftor.

    Drug: Ivacaftor · Drug: Placebo-matched-to-ivacaftor tablet

  • Experimental
    Placebo, Ivacaftor, Ivacaftor, Placebo (PIIP)

    During the Crossover Period, study drug was administered in 2-week alternating cycles with a minimum of 4-week washout period between Cycle 1 \[(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)\] and Cycle 2 \[(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)\] and between Cycle 2 and the Open-label Period (Day 1 to 57). During the Open-label Period, all participants received ivacaftor.

    Drug: Ivacaftor · Drug: Placebo-matched-to-ivacaftor tablet

  • Experimental
    Placebo, Ivacaftor, Placebo, Ivacaftor (PIPI)

    During the Crossover Period, study drug was administered in 2-week alternating cycles with a minimum of 4-week washout period between Cycle 1 \[(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)\] and Cycle 2 \[(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)\] and between Cycle 2 and the Open-label Period (Day 1 to 57). During the Open-label Period, all participants received ivacaftor.

    Drug: Ivacaftor · Drug: Placebo-matched-to-ivacaftor tablet

Interventions

  • 150 milligram (mg) tablet orally every 12 hours up to 12 weeks.

    Also known as: Kalydeco, VX-770

  • DrugPlacebo-matched-to-ivacaftor tablet

    Orally every 12 hours up to 4 weeks.

06

What researchers measure

Primary outcomes

  1. Cycle 1 and Cycle 2: Absolute Change From Cycle Baseline In Percent Predicted Forced Expiratory Volume In 1 Second (FEV1) After 2 Weeks of Treatment

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Hankinson and Wang standards were used to calculate percent predicted FEV1 (for age, gender, and height). The Hankinson standard was used for male participants 18 years and older and female participants 16 years and older. The Wang standard was used for male participants aged 12 to 17 years and for female participants aged 12 to 15 years. Data was to be reported for each cycle (Cycle 1 and Cycle 2) and as per drug treatment, for overall participants and as per genotype (residual function mutation and mRNA splice site mutation).

    Time frame: Cycle 1 baseline, Cycle 1 Day 15 (for Cycle 1 reporting arms); Cycle 2 baseline, Cycle 2 Day 15 (for Cycle 2 reporting arms)

Secondary outcomes

  1. Cycle 1 and Cycle 2: Absolute Change From Cycle Baseline In Lung Clearance Index (LCI) After 2 Weeks of Treatment

    LCI is a measure of ventilation inhomogeneity that is derived from a multiple-breath washout test. The LCI was calculated as the number of lung volume turnovers (cumulative expired volume divided by the functional residual capacity \[FRC\]) required to reduce end-tidal concentration of an inert gas to 1/40th of the starting value. Data was to be reported for each cycle (Cycle 1 and Cycle 2) and as per drug treatment. Data was to be reported for each cycle (Cycle 1 and Cycle 2) and as per drug treatment, for overall participants and as per genotype (residual function mutation and mRNA splice site mutation).

    Time frame: Cycle 1 baseline, Cycle 1 Day 15 (for Cycle 1 reporting arms); Cycle 2 baseline, Cycle 2 Day 15 (for Cycle 2 reporting arms)

  2. Open-label Period: Absolute Change From Open-label Baseline In Percent Predicted Forced Expiratory Volume In 1 Second (FEV1) at Day 57

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Hankinson and Wang standards were used to calculate percent predicted FEV1 (for age, gender, and height). The Hankinson standard was used for male participants 18 years and older and female participants 16 years and older. The Wang standard was used for male participants aged 12 to 17 years and for female participants aged 12 to 15 years. Data was to be reported for overall participants and as per genotype (residual function mutation and mRNA splice site mutation).

    Time frame: Open-label Baseline, Open-label Day 57

  3. Open-label Period: Absolute Change From Open-label Baseline In Lung Clearance Index (LCI) at Day 57

    LCI is a measure of ventilation inhomogeneity that is derived from a multiple-breath washout test. The LCI was calculated as the number of lung volume turnovers (cumulative expired volume divided by the functional residual capacity \[FRC\]) required to reduce end-tidal concentration of an inert gas to 1/40th of the starting value. Data was to be reported for overall participants and as per genotype (residual function mutation and mRNA splice site mutation).

    Time frame: Open-label Baseline, Open-label Day 57

  4. Open-label Period: Absolute Change From Study Baseline In Sweat Chloride at Day 57

    Sweat samples were collected using an approved Macroduct (Wescor, Logan, Utah) collection device. A volume of greater than or equal to (\>=) 15 microliter was required for determination of sweat chloride. Data was to be reported for overall participants and as per genotype (residual function mutation and mRNA splice site mutation).

    Time frame: Study Baseline, Open-label Day 57

  5. Open-label Period: Absolute Change From Open-label Baseline In Weight at Day 57

    Data was to be reported for overall participants and as per genotype (residual function mutation and mRNA splice site mutation).

    Time frame: Open-label Baseline, Open-label Day 57

  6. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Adverse events (AEs) that started (or increased in severity) from first dose of study drug through completion of Follow-up were considered TEAEs, with exception that if an AE started during a Washout Period and was beyond 14 days from last dose date of preceding cycle, AE was considered as a "Washout Period" AE, and hence not TEAE. A TEAE was attributed to treatment in which it started or to the treatment in second cycling period of previous Crossover Period if it started during a Washout Period. SAE: medical event or condition, which falls into any of following categories, regardless of its relationship to study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. Data was to be reported by drug treatment for double-blind crossover period (Cycle 1 up to Washout Period 2) and open-label period.

    Time frame: From first dose of study drug through completion of follow-up visit (up to 26 weeks)

07

Results

Posted May 19, 2015

Participant flow

Cycle 1 Period 1 (2 Weeks)
Participant flow — Cycle 1 Period 1 (2 Weeks)
MilestoneIvacaftor, Placebo, Ivacaftor, Placebo (IPIP)Ivacaftor, Placebo, Placebo, Ivacaftor (IPPI)Placebo, Ivacaftor, Ivacaftor, Placebo (PIIP)Placebo, Ivacaftor, Placebo, Ivacaftor (PIPI)
Started5676
Completed5676
Not completed0000
Cycle 1 Period 2 (2 Weeks)
Participant flow — Cycle 1 Period 2 (2 Weeks)
MilestoneIvacaftor, Placebo, Ivacaftor, Placebo (IPIP)Ivacaftor, Placebo, Placebo, Ivacaftor (IPPI)Placebo, Ivacaftor, Ivacaftor, Placebo (PIIP)Placebo, Ivacaftor, Placebo, Ivacaftor (PIPI)
Started5676
Completed5675
Not completed0001
Withdrew: Adverse event0001
Washout Period 1 (4 Weeks)
Participant flow — Washout Period 1 (4 Weeks)
MilestoneIvacaftor, Placebo, Ivacaftor, Placebo (IPIP)Ivacaftor, Placebo, Placebo, Ivacaftor (IPPI)Placebo, Ivacaftor, Ivacaftor, Placebo (PIIP)Placebo, Ivacaftor, Placebo, Ivacaftor (PIPI)
Started5675
Completed5675
Not completed0000
Cycle 2 Period 1 (2 Weeks)
Participant flow — Cycle 2 Period 1 (2 Weeks)
MilestoneIvacaftor, Placebo, Ivacaftor, Placebo (IPIP)Ivacaftor, Placebo, Placebo, Ivacaftor (IPPI)Placebo, Ivacaftor, Ivacaftor, Placebo (PIIP)Placebo, Ivacaftor, Placebo, Ivacaftor (PIPI)
Started5675
Completed5675
Not completed0000
Cycle 2 Period 2 (2 Weeks)
Participant flow — Cycle 2 Period 2 (2 Weeks)
MilestoneIvacaftor, Placebo, Ivacaftor, Placebo (IPIP)Ivacaftor, Placebo, Placebo, Ivacaftor (IPPI)Placebo, Ivacaftor, Ivacaftor, Placebo (PIIP)Placebo, Ivacaftor, Placebo, Ivacaftor (PIPI)
Started5675
Completed5574
Not completed0101
Withdrew: Non-compliance with study drug0101
Washout Period 2 (4 Weeks)
Participant flow — Washout Period 2 (4 Weeks)
MilestoneIvacaftor, Placebo, Ivacaftor, Placebo (IPIP)Ivacaftor, Placebo, Placebo, Ivacaftor (IPPI)Placebo, Ivacaftor, Ivacaftor, Placebo (PIIP)Placebo, Ivacaftor, Placebo, Ivacaftor (PIPI)
Started5574
Completed5574
Not completed0000
Open-label Period (8 Weeks)
Participant flow — Open-label Period (8 Weeks)
MilestoneIvacaftor, Placebo, Ivacaftor, Placebo (IPIP)Ivacaftor, Placebo, Placebo, Ivacaftor (IPPI)Placebo, Ivacaftor, Ivacaftor, Placebo (PIIP)Placebo, Ivacaftor, Placebo, Ivacaftor (PIPI)
Started5574
Completed5574
Not completed0000

Outcome measures

PrimaryCycle 1 and Cycle 2: Absolute Change From Cycle Baseline In Percent Predicted Forced Expiratory Volume In 1 Second (FEV1) After 2 Weeks of Treatment

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Hankinson and Wang standards were used to calculate percent predicted FEV1 (for age, gender, and height). The Hankinson standard was used for male participants 18 years and older and female participants 16 years and older. The Wang standard was used for male participants aged 12 to 17 years and for female participants aged 12 to 15 years. Data was to be reported for each cycle (Cycle 1 and Cycle 2) and as per drug treatment, for overall participants and as per genotype (residual function mutation and mRNA splice site mutation).

Time frame:
Cycle 1 baseline, Cycle 1 Day 15 (for Cycle 1 reporting arms); Cycle 2 baseline, Cycle 2 Day 15 (for Cycle 2 reporting arms)
Reported as:
Mean · Percent predicted of FEV1
Cycle 1 and Cycle 2: Absolute Change From Cycle Baseline In Percent Predicted Forced Expiratory Volume In 1 Second (FEV1) After 2 Weeks of Treatment
Percent predicted of FEV1Cycle 1: PlaceboCycle 1: IvacaftorCycle 2: PlaceboCycle 2: Ivacaftor
Overall (n=24, 24, 23, 23)0.5828 ± 3.673262.0898 ± 4.638330.8495 ± 4.206413.6868 ± 6.13466
mRNA Splice Site(ClassV)Mutations (n=10, 10, 9, 9)-0.5710 ± 3.397390.8196 ± 5.091611.7132 ± 3.809332.0640 ± 3.55493
Residual Function Mutations (n=14, 14, 14, 14)1.4069 ± 3.758422.9971 ± 4.241240.2942 ± 4.490564.7300 ± 7.27436
Statistical analysis
  • Cycle 1: Placebo vs Cycle 1: Ivacaftor vs Cycle 2: Placebo vs Cycle 2: Ivacaftor · Posterior mean: 2.251 · 95% CI 0.383 to 4.144The posterior distribution of overall treatment difference was obtained using the Bayesian hierarchical model and 95% credible interval of the treatment effect (posterior mean) was calculated.
SecondaryCycle 1 and Cycle 2: Absolute Change From Cycle Baseline In Lung Clearance Index (LCI) After 2 Weeks of Treatment

LCI is a measure of ventilation inhomogeneity that is derived from a multiple-breath washout test. The LCI was calculated as the number of lung volume turnovers (cumulative expired volume divided by the functional residual capacity \[FRC\]) required to reduce end-tidal concentration of an inert gas to 1/40th of the starting value. Data was to be reported for each cycle (Cycle 1 and Cycle 2) and as per drug treatment. Data was to be reported for each cycle (Cycle 1 and Cycle 2) and as per drug treatment, for overall participants and as per genotype (residual function mutation and mRNA splice site mutation).

Time frame:
Cycle 1 baseline, Cycle 1 Day 15 (for Cycle 1 reporting arms); Cycle 2 baseline, Cycle 2 Day 15 (for Cycle 2 reporting arms)
Reported as:
Mean · ratio
Cycle 1 and Cycle 2: Absolute Change From Cycle Baseline In Lung Clearance Index (LCI) After 2 Weeks of Treatment
ratioCycle 1: PlaceboCycle 1: IvacaftorCycle 2: PlaceboCycle 2: Ivacaftor
Overall (n=23, 24, 23, 22)0.4596 ± 1.977740.2822 ± 3.547410.4111 ± 2.399200.0770 ± 1.98188
mRNA Splice Site(ClassV)Mutations (n=10, 10, 9, 9)0.4321 ± 1.97140-0.5306 ± 1.913741.0568 ± 2.12093-0.3136 ± 1.89562
Residual Function Mutations (n=13, 14, 14, 13)0.4808 ± 2.062790.8628 ± 4.34252-0.0039 ± 2.549290.3475 ± 2.06990
SecondaryOpen-label Period: Absolute Change From Open-label Baseline In Percent Predicted Forced Expiratory Volume In 1 Second (FEV1) at Day 57

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Hankinson and Wang standards were used to calculate percent predicted FEV1 (for age, gender, and height). The Hankinson standard was used for male participants 18 years and older and female participants 16 years and older. The Wang standard was used for male participants aged 12 to 17 years and for female participants aged 12 to 15 years. Data was to be reported for overall participants and as per genotype (residual function mutation and mRNA splice site mutation).

Time frame:
Open-label Baseline, Open-label Day 57
Reported as:
Mean · Percent predicted of FEV1
Open-label Period: Absolute Change From Open-label Baseline In Percent Predicted Forced Expiratory Volume In 1 Second (FEV1) at Day 57
Percent predicted of FEV1Open-Label Period: Ivacaftor
Overall (n=21)4.6815 ± 4.17934
mRNA Splice Site(ClassV)Mutations (n=9)4.3072 ± 2.93624
Residual Function Mutations (n=12)4.9622 ± 5.02864
SecondaryOpen-label Period: Absolute Change From Open-label Baseline In Lung Clearance Index (LCI) at Day 57

LCI is a measure of ventilation inhomogeneity that is derived from a multiple-breath washout test. The LCI was calculated as the number of lung volume turnovers (cumulative expired volume divided by the functional residual capacity \[FRC\]) required to reduce end-tidal concentration of an inert gas to 1/40th of the starting value. Data was to be reported for overall participants and as per genotype (residual function mutation and mRNA splice site mutation).

Time frame:
Open-label Baseline, Open-label Day 57
Reported as:
Mean · ratio
Open-label Period: Absolute Change From Open-label Baseline In Lung Clearance Index (LCI) at Day 57
ratioOpen-label Period: Ivacaftor
Overall (n=21)-1.5687 ± 2.27137
mRNA Splice Site(ClassV)Mutations (n=9)-1.3459 ± 2.88447
Residual Function Mutations (n=12)-1.7358 ± 1.80502
SecondaryOpen-label Period: Absolute Change From Study Baseline In Sweat Chloride at Day 57

Sweat samples were collected using an approved Macroduct (Wescor, Logan, Utah) collection device. A volume of greater than or equal to (\>=) 15 microliter was required for determination of sweat chloride. Data was to be reported for overall participants and as per genotype (residual function mutation and mRNA splice site mutation).

Time frame:
Study Baseline, Open-label Day 57
Reported as:
Mean · millimole per liter (mmol/L)
Open-label Period: Absolute Change From Study Baseline In Sweat Chloride at Day 57
millimole per liter (mmol/L)Open-label Period: Ivacaftor
Overall (n=19)-15.74 ± 14.781
mRNA Splice Site(ClassV)Mutations (n=8)-14.13 ± 8.254
Residual Function Mutations (n=11)-16.91 ± 18.493
SecondaryOpen-label Period: Absolute Change From Open-label Baseline In Weight at Day 57

Data was to be reported for overall participants and as per genotype (residual function mutation and mRNA splice site mutation).

Time frame:
Open-label Baseline, Open-label Day 57
Reported as:
Mean · kilograms (kg)
Open-label Period: Absolute Change From Open-label Baseline In Weight at Day 57
kilograms (kg)Open-label Period: Ivacaftor
Overall (n=21)1.77 ± 1.906
mRNA Splice Site(ClassV)Mutations (n=9)2.32 ± 2.111
Residual Function Mutations (n=12)1.35 ± 1.710
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

Adverse events (AEs) that started (or increased in severity) from first dose of study drug through completion of Follow-up were considered TEAEs, with exception that if an AE started during a Washout Period and was beyond 14 days from last dose date of preceding cycle, AE was considered as a "Washout Period" AE, and hence not TEAE. A TEAE was attributed to treatment in which it started or to the treatment in second cycling period of previous Crossover Period if it started during a Washout Period. SAE: medical event or condition, which falls into any of following categories, regardless of its relationship to study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. Data was to be reported by drug treatment for double-blind crossover period (Cycle 1 up to Washout Period 2) and open-label period.

Time frame:
From first dose of study drug through completion of follow-up visit (up to 26 weeks)
Reported as:
Number · participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
participantsCrossover Double-blind Period: PlaceboCrossover Double-blind Period: IvacaftorOpen-label Period: Ivacaftor
AEs171820
SAEs010

Adverse events

Collected over From first dose of study drug through completion of follow-up visit (up to 26 weeks). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Crossover Double-blind Period: Placebo—0/24 (0%)17/24 (70.8%)
Crossover Double-blind Period: Ivacaftor—1/24 (4.2%)18/24 (75%)
Open-label Period: Ivacaftor—0/21 (0%)20/21 (95.2%)
Most frequent serious events
Most frequent serious events
EventCrossover Double-blind Period: PlaceboCrossover Double-blind Period: IvacaftorOpen-label Period: Ivacaftor
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations0/241/240/21
Most frequent other events
Showing 10 of 68
Most frequent other events
EventCrossover Double-blind Period: PlaceboCrossover Double-blind Period: IvacaftorOpen-label Period: Ivacaftor
CoughRespiratory, thoracic and mediastinal disorders6/241/247/21
Sputum increasedRespiratory, thoracic and mediastinal disorders7/241/242/21
Upper respiratory tract infectionInfections and infestations0/245/244/21
FatigueGeneral disorders3/240/244/21
DyspnoeaRespiratory, thoracic and mediastinal disorders4/240/241/21
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations3/241/242/21
Oral candidiasisInfections and infestations3/240/240/21
PyrexiaGeneral disorders1/243/240/21
HaemoptysisRespiratory, thoracic and mediastinal disorders0/241/242/21
Oropharyngeal painRespiratory, thoracic and mediastinal disorders1/241/242/21

Baseline characteristics

Full Analysis Set (FAS) included all randomized participants who received at least 1 dose of study drug (ivacaftor or placebo).

Age, Continuous
Age, Continuous(years)IPIPIPPIPIIPPIPITotal
Mean44.8 ± 8.0429.7 ± 11.6641.4 ± 13.9633.8 ± 17.2637.3 ± 13.86
Age, Customized
Age, Customized(participants)IPIPIPPIPIIPPIPITotal
less than (<) 20 years01023
20 - 40 years143210
greater than (>) 40 years414211
Sex: Female, Male
Sex: Female, Male(Participants)IPIPIPPIPIIPPIPITotal
Female343212
Male224412
Genotype
Genotype(participants)IPIPIPPIPIIPPIPITotal
mRNA Splice Site (Class V) Mutations332210
Residual Function Mutations235414
08

Study locations

1 site
  • Denver, Colorado, United States
09

References and documents

Publications

  • Nick JA, St Clair C, Jones MC, Lan L, Higgins M; VX12-770-113 Study Team. Ivacaftor in cystic fibrosis with residual function: Lung function results from an N-of-1 study. J Cyst Fibros. 2020 Jan;19(1):91-98. doi: 10.1016/j.jcf.2019.09.013. Epub 2019 Nov 26. PubMed 31784217 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2012, a primary completion of Apr 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.

Results were first posted in May 2015, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2012
First posted
Sep 14, 2012
Start
Sep 2012
Primary completionActual
Apr 2014
CompletionActual
Apr 2014
Results first posted
May 19, 2015
Last update
May 19, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01685801
Responsible party
Sponsor
First posted
Sep 14, 2012
Start date
Sep 2012
Primary completion
Apr 2014
Completion
Apr 2014
Results posted
May 19, 2015
Last update
May 19, 2015

Study contacts

Jerry Nick, MD
principal investigator · National Jewish Health

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivacaftor

Start the discussion